

NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)**Oesophago-Gastric Cancer****First Guideline Development Group (GC) meeting**23rd & 24th March 2016

Royal College of Obstetricians and Gynaecologists (RCOG)

GROUP MEMBERSHIP & ACTION LIST

GC Members	
Mr Cyrus Kerawala (Chair) (CK)	Mr Mark Harrison (MH)
Mr David Exon (DE)	Dr Andrew Bateman (ABa)
Dr Hugh Burnett (HB)	Dr Naureen Starling (NS)
Ms Venetia Wynter-Blyth (VWB)	Mr David Simpson (DS)
Miss Orla Hynes (OH)	Mrs Mimi McCord (MM)
NCC-C staff	
John Graham (JG)	Ferrucio Pelone (FP)
Angela Bennett (AB)	Matthew Prettyjohns (MP)
Sabine Berendse (SB)	Nathan Bromham (NB)
Natasha Pillai (NP)	
NICE staff	
Caroline Keir (CKe)	Adam Storrow (AS) (<i>Day 1 only</i>)
Juliet Kenny (JK) (<i>Day 1 only</i>)	
Apologies	
Mr Nick Maynard (<i>Day 1 & 2</i>) (NM)	Katie Perryman Ford (<i>Day 1 & 2</i>) (KPF)
Dr Robert Willert (<i>Day 1 & 2</i>) (RW)	Andy Champion (<i>Day 1 & 2</i>) (AC)
David Brooks (<i>Day 1 & 2</i>) (DB)	Lianne Gwillim (<i>Day 1 & 2</i>) (LG)
Ferrucio Pelone (<i>Day 2</i>) (FP)	

REPORTS OF DISCUSSIONS AT THE MEETING**1. Introductions**

CK welcomed everyone to the 1st meeting of the Oesophago-Gastric GC.

2. Declarations of Interest

The following declarations of interest were declared prior to the meeting:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Venetia Wynter-Blyth	UGI Clinical Nurse Specialist, Imperial College NHS Trust	Received honorarium and travel expenses from Lilly Oncology in October 2015 for presenting on the role of the CNS in upper GI cancer at the UGI CNS forum [Declared on application form - January	Personal Financial Non Specific	No action needed as role of the CNS in upper GI Cancers is not being covered by

		2016]		the guideline.
Venetia Wynter-Blyth	UGI Clinical Nurse Specialist, Imperial College NHS Trust	Received honorarium from Lilly Oncology in November 2015 for participating in Advisory Board on upper GI cancer nutrition: education and awareness. [Declared on application form - January 2016]	Non Personal Financial Specific (4.10 & 4.11)	Withdraw from discussion on clinical question 4.10 & 4.11 until November 2016.
Venetia Wynter-Blyth	UGI Clinical Nurse Specialist, Imperial College NHS Trust	Funding from 2 charity grants from Imperial College and funding from Health Education North West London to run the preparation for surgery programme. [Declared on application form - January 2016]	Non Personal Financial Non Specific	No Action Needed
Venetia Wynter-Blyth	UGI Clinical Nurse Specialist, Imperial College NHS Trust	Has a Quality and Improvement fellowship from NIHR Clahrac for continued professional development. [Declared on application form - January 2016]	Personal Financial Non Specific	No Action Needed
Venetia Wynter-Blyth	UGI Clinical Nurse Specialist, Imperial College NHS Trust	Has been asked to be a CNS advisor on the GASTRO study (NIHR funded). Not yet accepted this invitation. [Declared on application form - January 2016]	Non Personal Financial Non Specific/Specific	No Action Needed
Venetia Wynter-Blyth	UGI Clinical Nurse Specialist, Imperial College NHS Trust	Council member of AUGIS. Represents the role of the CNS, organises an annual CNS training day and an annual CNS meeting to discuss professional development and advances in the upper GI field. No fees received. Term of office ends in April 2016. [Declared on application form - January 2016]	Non-Financial Non Specific	No Action Needed
Venetia Wynter-Blyth	UGI Clinical Nurse Specialist, Imperial College NHS Trust	Has a comment column in the quarterly AUGIS newsletter. Highlights areas of uncertainty/variation in surgery for upper GI	Non-Financial Non Specific	No Action Needed. The guideline will not focus on

		cancer (e.g. the need involvement of the CNS in post-op follow up, pre-op preparation). Used to stimulate discussion, rather than providing solutions. [Declared on application form - January 2016]		who should do it.
Venetia Wynter-Blyth	UGI Clinical Nurse Specialist, Imperial College NHS Trust	Is advising on the development of a platform to remotely monitor pre-op upper GI cancer patients – its use will be piloted as part of the preparation for surgery programme. Development of the platform is funded by Medtronic. No fees received. If pilot of the platform is successful then it may be rolled out more widely. Any money generated will be used to refine and further develop the platform. No fees will be received. [Declared on application form - January 2016]	Non-Financial Non Specific	No Action Needed.
Andrew Bateman	Consultant Clinical Oncologist, University Hospital Southampton NHS Foundation Trust	None Declared		
Orla Hynes	Senior Specialist Upper GI Benign and Cancer Surgery Dietitian, Guy's & St Thomas' NHS Foundation Trust	British Dietetic Association paid travel expenses to attend a task and finish group preparing an outcome tool for cancer patients – July 2015 and January 2016. [Declared on application form - January 2016]	Personal Financial Non Specific	No Action Needed
Orla Hynes	Senior Specialist Upper GI Benign and Cancer Surgery Dietitian, Guy's & St Thomas' NHS Foundation Trust	Member of the British Dietetic Association sub group for OG cancer. [Declared on application form - January 2016]	Non-Financial Specific	No Action Needed
Orla Hynes	Senior Specialist Upper GI Benign and Cancer	AHP lead for the London Cancer Alliance OG cancer pathways working	Non-Financial Specific	No Action Needed

	Surgery Dietitian, Guy's & St Thomas' NHS Foundation Trust	group. [Declared on application form - January 2016]		
Orla Hynes	Senior Specialist Upper GI Benign and Cancer Surgery Dietitian, Guy's & St Thomas' NHS Foundation Trust	Principal investigator on a CRN portfolio study investigating peri-operative anaemia management. A prospective cohort study funded by St Thomas Hospital and CRUK. [Declared on application form - January 2016]	No Action Needed	No Action Needed
Robert Willert	Consultant Gastroenterologist, Manchester Royal Infirmary (Central Manchester University Hospitals NHS Foundation Trust)	Received travel expenses from US Endoscopy in April 2015 to advise them on the use of new endoscopic therapeutic equipment that they are developing for use in general endoscopy. [Declared on application form - January 2016]	Personal Financial Non Specific/ Specific	Leave room for discussion on Endoscopic Therapeutic equipment until April 2016.
Robert Willert	Consultant Gastroenterologist, Manchester Royal Infirmary (Central Manchester University Hospitals NHS Foundation Trust)	Received a fee from Takeda in June 2015 for attending an advisory board on vedolizumab in inflammatory bowel disease. [Declared on application form - January 2016]	Personal Financial Non Specific	No Action Needed
Robert Willert	Consultant Gastroenterologist, Manchester Royal Infirmary (Central Manchester University Hospitals NHS Foundation Trust)	Received payment from MSD for giving a presentation in December 2015 on the endoscopic management of inflammatory bowel disease. [Declared on application form - January 2016]	Personal Financial Non Specific	No Action Needed
Robert Willert	Consultant Gastroenterologist, Manchester Royal Infirmary (Central Manchester University Hospitals NHS Foundation Trust)	Received travel/subsistence from Abbvie to attend the Digestive Disorders Week in May 2015. [Declared on application form - January 2016]	Personal Financial Non Specific	No Action Needed
Robert Willert	Consultant Gastroenterologist, Manchester Royal Infirmary (Central Manchester University Hospitals NHS Foundation Trust)	Has an agreement with Takeda to provide travel subsistence expenses to attend the Digestive	Personal Financial Non Specific	No Action Needed

	Manchester University Hospitals NHS Foundation Trust)	Disorders Week May 2016. [Declared on application form - January 2016]		
Robert Willert	Consultant Gastroenterologist, Manchester Royal Infirmary (Central Manchester University Hospitals NHS Foundation Trust)	Principal investigator for a phase II study on a JAK1 inhibitor for treating inflammatory bowel disease. Study funded by Abbvie. No involvement in designing trial protocol. [Declared on application form - January 2016]	Non Personal Financial Non Specific	No Action Needed
Robert Willert	Consultant Gastroenterologist, Manchester Royal Infirmary (Central Manchester University Hospitals NHS Foundation Trust)	Principal investigator for a multi-national, multi-centre study on the antibiotic Cadazolid/ACT-179811 for treating Clostridium difficile-associated diarrhoea. Funded by ACTELION Pharmaceuticals Ltd. [Declared on application form - January 2016]	Non Personal Financial Non Specific	No Action Needed
Robert Willert	Consultant Gastroenterologist, Manchester Royal Infirmary (Central Manchester University Hospitals NHS Foundation Trust)	Principal investigator for a randomised control trial of surveillance and no surveillance for patients with Barrett's oesophagus (BOSS). Funded by HTA. [Declared on application form - January 2016]	Non Personal Financial Non Specific	No Action Needed
Robert Willert	Consultant Gastroenterologist, Manchester Royal Infirmary (Central Manchester University Hospitals NHS Foundation Trust)	Contributes patient data to the National HALO RFA registry – run by UCL. [Declared on application form - January 2016]	Non-Financial Non Specific	No Action Needed
Robert Willert	Consultant Gastroenterologist, Manchester Royal Infirmary (Central Manchester University Hospitals NHS Foundation Trust)	Is a fund holder for a charitable research fund used to purchase new equipment, staff CPD for the department (no specific OG cancer focus). No industry contributions to this fund for the last 12 months. [Declared on application form - January 2016]	Non-Financial Non Specific	No Action Needed

Robert Willert	Consultant Gastroenterologist, Manchester Royal Infirmary (Central Manchester University Hospitals NHS Foundation Trust)	Member of the OG cancer sub-group of the Manchester Cancer Board. Develop guidelines/pathways for the treatment of OG cancer in Greater Manchester. [Declared on application form - January 2016]	Non-Financial Specific	No Action Needed
Naureen Starling	Medical Oncologist, Royal Marsden Hospital	Pfizer advisory board (biosimilars) 2015; compensated. [Declared on application form - January 2016]	More information needed	
Naureen Starling	Medical Oncologist, Royal Marsden Hospital	BMS International immuno-oncology translational collaboration meeting (Jan 2016) – non-compensated. [Declared on application form - January 2016]	Non-Financial Non Specific	No Action Needed
David Brooks	Macmillan Consultant in Palliative Medicine at the Chesterfield and North Derbyshire Hospital NHS Trust	I am a member of the Executive Committee of the Association for Palliative Medicine and Immediate Past President. [Declared on application form - January 2016]	Non-Financial Non Specific	No Action Needed
David Simpson	Patient/Carer Member	Receives a fee for taking part in peer review of MDTs against cancer standards. Looked at Haematology in 2015 and will be looking at cancer of unknown primary in 2016. [Declared on application form - January 2016]	Personal Financial Non Specific	No Action Needed
David Simpson	Patient/Carer Member	Is a Director of Central Bedfordshire Healthwatch. Is a voluntary post – no fees received (only reimbursement of travel expenses). Healthwatch is funded by the Department of Health and acts as watchdog for patients in health and social care. Role is to lead on the	Non-Financial Non Specific	No Action Needed

		'Enter and View' project which looked at nursing homes in 2015 and will be looking at GP surgeries in 2016. [Declared on application form - January 2016]		
David Simpson	Patient/Carer Member	Volunteer speaker for Macmillan on general cancer awareness and education about services offered by Macmillan. No fees receive – reimbursement of travel expenses only. [Declared on application form - January 2016]	Personal Financial Non Specific	No Action Needed
David Simpson	Patient/Carer Member	Member of the upper GI site specific group of the East of England Cancer Network – no fees received. [Declared on application form - January 2016]	Non-Financial Specific	No Action Needed
David Simpson	Patient/Carer Member	Member of the East of England Cancer Network Acute Oncology group. No fees received. [Declared on application form - January 2016]	Non-Financial Specific	No Action Needed
Mimi McCord	Patient/Carer Member	Lay member of ABBA advisory committee (A feasibility study with a crossover design to assess the diagnostic accuracy of acetic acid targeted biopsies versus non targeted biopsies (current practice) for detection of dysplasia during Barrett's surveillance). Funded by NIHR. No reimbursement received. [Declared on application form - January 2016]	Non-Financial Non Specific	No Action Needed
Mimi McCord	Patient/Carer Member	Lay member of the advisory committee on evaluation of non-endoscopic immunocytological device (Cytosponge) for Barrett's Esophagus Screening.	Non-Financial Non Specific	No Action Needed

		Funded by CRUK. No reimbursement received. [Declared on application form - January 2016]		
Mimi McCord	Patient/Carer Member	Chairman Trustee and Director of Heartburn Cancer UK (HCUK). Voluntary organisation with no paid employees. Purpose is to raise awareness and educate the public and healthcare professionals on the signs and symptoms of oesophago-gastric cancer. Charity is funded by donations with occasional donations from industry to support specific awareness raising initiatives. Board of Trustee's is responsible for signing off spends for large amounts of money. Sign off for spends of small amounts can be done by the Chairman Trustee. [Declared on application form - January 2016]	Non Financial Specific	No Action Needed.
Mimi McCord	Patient/Carer Member	Lay co-author on a stricture guideline for the British Society of Gastroenterology. [Declared on application form - January 2016]	Non-Financial Non Specific	No Action Needed
Mimi McCord	Patient/Carer Member	Lay member of the expert panel advising the Department of Health of the key messages to trial a public awareness symptoms campaign for oesophago-gastric cancer. [Declared on application form - January 2016]	Non-Financial Non-Specific	No Action Needed
Mimi McCord	Patient/Carer Member	Has given radio interviews and been quoted in press releases about raising awareness of the signs and symptoms of oesophago-gastric cancer. [Declared on application form - January	Non-Financial Non-Specific	No Action Needed as signs and symptoms of oesophago-gastric cancer is not covered by

		2016]		this guideline.
Hugh Burnett	Consultant Radiologist, Salford Royal Hospitals	None Declared		
David Exon	Consultant Upper GI Surgeon, University Hospitals of Leicester NHS Trust	Supervised a research fellow on a retrospective study on paraffin sections to identify prognostic markers for OG cancer. Funded by Nine Wells Hospital. Study has finished but if data is written up and published, will be an author on the paper. [Declared on application form - January 2016]	Non Personal Financial Non Specific/Specific	No Action Needed as no supervisory responsibility and study not funded by industry.
David Exon	Consultant Upper GI Surgeon, University Hospitals of Leicester NHS Trust	Contributed patients to a study on enteral nutrition in post-oesophagectomy patients. Study run locally by University Hospitals of Leicester and finished in 2015. Not funded by industry. [Declared on application form - January 2016]	Non-Financial Specific	No Action Needed
David Exon	Consultant Upper GI Surgeon, University Hospitals of Leicester NHS Trust	Member of the Expert Clinical Advisory Group for East Midlands. Group decides on pathways for treatment of OG cancer in East Midlands. [Declared on application form - January 2016]	Non-Financial Specific	No Action Needed
Nick Maynard	Consultant Upper GI Surgeon, Oxford University Hospitals NHS Foundation Trust	Is paid a fee and has travel reimbursed by Synapse for demonstrating the use of their diaphragmatic pace-maker at various locations in Europe. [Declared on application form - January 2016]	Personal Financial Specific	No Action Needed
Nick Maynard	Consultant Upper GI Surgeon, Oxford University Hospitals NHS Foundation Trust	Local lead investigator for the AspECT study (A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia). Drug support provided by Astra Zeneca. Not	Non Personal Financial Non Specific	No Action Needed

		involved in designing the trial protocol. [Declared on application form - January 2016]		
Nick Maynard	Consultant Upper GI Surgeon, Oxford University Hospitals NHS Foundation Trust	Contributes patients to oesophago gastric cancer-related trials (NEO-AEGIS and ST03). No involvement in the trials themselves. [Declared on application form - January 2016]	Non-Financial Specific	No Action Needed
Nick Maynard	Consultant Upper GI Surgeon, Oxford University Hospitals NHS Foundation Trust	Has financial sign off on a fund which is used for CPD of departmental staff. No industry contribution to this fund. [Declared on application form - January 2016]	Non Personal Financial Non Specific	No Action Needed
Nick Maynard	Consultant Upper GI Surgeon, Oxford University Hospitals NHS Foundation Trust	Is a Trustee of the Oxford Oesophagus and Stomach Organisation. Involves reviewing the finances of this charity. No remuneration received. [Declared on application form - January 2016]	Non-Financial Specific	No Action Needed
Nick Maynard	Consultant Upper GI Surgeon, Oxford University Hospitals NHS Foundation Trust	Is the Chair of Clinical Services and audit for AUGIS. No remuneration received. [Declared on application form - January 2016]	Non-Financial Specific	No Action Needed

The GC were reminded that if they take on any new interests, these must be declared to the NCC-C as soon as they happen so that the necessary action can be taken.

3. Discussions

The GC were given presentations on:

- Introduction to NICE
- Introduction to NCC-C
- Timetable for guideline development and housekeeping
- Patient/Carer involvement in guideline development
- Guideline methodology development: From evidence to recommendations
- Guideline methodology development: Health Economics in NICE guidelines
- Technology appraisals and clinical guidelines.

The GC discussed the guideline scope and the topics that will be investigated. The group then drafted and agreed a PICO table for questions 4.7, 4.8, 4.9, 3.1, 3.2, 3.3, 4.1, 4.2, 4.3, 4.4, 4.6, 4.10 and 4.11. They also discussed the priority for economic investigation for each of these questions.

4. Close of meeting

5. CK thanked the GC for their input to the meeting, reminded them that the next meeting would be on **Friday 22nd April 2016**, starting at 10.45am at the RCOG, 27 Sussex Place, Regent's Park, London, NW1 4RG (room TBC).